Abstract: Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40. Such antibodies optionally comprise Fc regions with enhanced specificity for Fc?RIIb. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.
Type:
Application
Filed:
November 18, 2019
Publication date:
March 5, 2020
Applicants:
The Rockefeller University, BRISTOL-MYERS SQUIBB COMPANY
Inventors:
Jeffrey V. Ravetch, Rony Dahan, Bryan C. Barnhart, Brigitte Devaux, Aaron P. Yamniuk, Shannon L. Okada, Brenda L. Stevens
Abstract: The present invention discloses novel agents and methods for diagnosis and treatment of melanoma. Also disclosed are related arrays, kits, and screening methods.
Abstract: The present invention provides methods, compositions and articles of manufacture useful for the prophylactic and therapeutic amelioration and treatment of gram-positive bacteria, including Streptococcus and Staphylococcus, and related conditions. The invention provides compositions and methods incorporating and utilizing Streptococcus suis derived bacteriophage lysins, particularly PlySs2 and/or PlySs1 lytic enzymes and variants thereof, including truncations thereof. Methods for treatment of humans are provided.
Type:
Grant
Filed:
April 20, 2017
Date of Patent:
January 28, 2020
Assignee:
The Rockefeller University
Inventors:
Vincent A. Fischetti, Jonathan Schmitz, Daniel Gilmer, Chad Euler
Abstract: 2-Acylindazole compounds of formula I or formula II are disclosed: These compounds inhibit Coagulation Factor XIIa. They are useful to treat autoimmune diseases.
Type:
Grant
Filed:
May 22, 2017
Date of Patent:
January 21, 2020
Assignee:
The Rockefeller University
Inventors:
Manish P. Ponda, Jan L. Breslow, Harold Selnick, Melissa Egbertson
Abstract: This invention concerns pathological angiogenesis and cancer, related treatment methods, and related compositions. Also disclosed are related diagnosis kits and methods.
Abstract: Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40. Such antibodies optionally comprise Fc regions with enhanced specificity for Fc?RIIb. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.
Type:
Grant
Filed:
June 28, 2016
Date of Patent:
November 19, 2019
Assignees:
Bristol-Myers Squibb Company, The Rockefeller University
Inventors:
Jeffrey V. Ravetch, Rony Dahan, Bryan C. Barnhart, Brigitte Devaux, Aaron P. Yamniuk, Shannon L. Okada, Brenda L. Stevens
Abstract: The invention provides for systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells and methods for selecting specific cells by introducing precise mutations utilizing the CRISPR/Cas system.
Type:
Application
Filed:
November 1, 2018
Publication date:
September 26, 2019
Applicants:
The Broad Institute, Inc., Massachusetts Institute of Technology, The Rockefeller University
Inventors:
Feng ZHANG, David Benjamin Turitz COX, Luciano MARRAFFINI, David Olivier BIKARD, Wenyan JIANG, Neville Epsi SANJANA
Abstract: The present invention relates to broadly neutralizing anti-HIV-1 antibodies and isolated antigens. Also disclosed are related methods and compositions.
Type:
Grant
Filed:
January 30, 2015
Date of Patent:
September 24, 2019
Assignees:
The Rockefeller University, California Institute of Technology
Inventors:
Michel Nussenzweig, Pamela J. Bjorkman, Louise Scharf, Johannes Scheid
Abstract: The present invention discloses novel agents and methods for diagnosis and treatment of colon cancer. Also disclosed are related arrays, kits, and screening methods.
Abstract: The present invention provides isolated dimeric Streptococcus-specific phage lysins having two Streptococcus-specific phage lysin monomers covalently linked to each other, and having killing activity against one or more Streptococcus bacteria. Also provided for are pharmaceutical compositions of dimeric lysins and their use in therapeutic treatment or alleviation of infections or bacterial colonizations. The dimeric lysins may also be used to decontaminate porous and non-porous surfaces or devices.
Abstract: The present invention relates to anti-HIV antibodies. Also disclosed are related methods and compositions. HIV causes acquired immunodeficiency syndrome (AIDS), a condition in humans characterized by clinical features including wasting syndromes, central nervous system degeneration and profound immunosuppression that results in life-threatening opportunistic infections and malignancies. Since its discovery in 1981, HIV type 1 (HIV-1) has led to the death of at least 25 million people worldwide.
Type:
Grant
Filed:
June 12, 2018
Date of Patent:
August 27, 2019
Assignees:
The Rockefeller University, California Institute of Technology
Inventors:
Hugo Mouquet, Michel Nussenzweig, Pamela J. Bjorkman, Louise Scharf
Abstract: The invention relates to compositions, methods, kits, and assays related to the use and/or exploitation of isomers of cGAMP as well as the structure of the enzyme cGAS.
Type:
Grant
Filed:
September 28, 2017
Date of Patent:
August 20, 2019
Assignees:
Memorial Sloan Kettering Cancer Center, The Rockefeller University, Rutgers, The State University of New Jersey, University of Bonn
Inventors:
Dinshaw J. Patel, Thomas Tuschl, Manuel Ascano, Jr., Yang Wu, Yizhou Liu, Winfried Barchet, Gunther Hartmann, Thomas Zillinger, Roger Jones, Barbara L. Gaffney, Pu Gao
Abstract: The present disclosure provides antibodies that specifically bind to Mer Tyrosine Kinase (MERTK) (e.g., human MERTK, or both human and mouse MERTK) and compositions comprising such antibodies, wherein said antibody agonizes MERTK signaling on endothelial cells. The present disclosure also provides methods for treating cancer, by administering an antibody that specifically binds to MERTK and agonizes MERTK signaling on endothelial cells.
Type:
Application
Filed:
January 24, 2019
Publication date:
August 8, 2019
Applicant:
The Rockefeller University
Inventors:
Sohail Tavazoie, Nils Halberg, Masoud Tavazoie
Abstract: 2-Acylindazole compounds of formula I or formula II are disclosed: These compounds inhibit Coagulation Factor XIIa. They are useful to treat autoimmune diseases.
Type:
Application
Filed:
May 22, 2017
Publication date:
July 4, 2019
Applicant:
The Rockefeller University
Inventors:
Manish P. PONDA, Jan L. BRESLOW, Harold SELNICK, Melissa EGBERTSON
Abstract: In one embodiment, the present invention relates to a method for optimizing cell-type specific protein expression. In another embodiment, the present invention relates to a method for creating a tRNA profile of a cell.
Abstract: Treatment of neurodegenerative diseases is achieved using small molecule purine scaffold compounds that inhibit Hsp90 and that possess the ability to cross the blood-brain barrier or are other wise delivered to the brain.
Type:
Grant
Filed:
July 2, 2007
Date of Patent:
July 2, 2019
Assignees:
Sloan-Kettering Institute for Cancer Research, The Rockefeller University
Abstract: Compositions and methods disclosed concern an isogenic population of in vitro human embryonic stem cells comprising a disease form of the Huntingtin gene (HTT) at the endogenous HTT gene locus in the genome of the cell; wherein the disease form of the HTT gene comprises a polyQ repeat of at least 40 glutamines at the N-terminus of the Huntingtin protein (HTT). The cell lines of the disclosure comprise genetically-defined alterations made in the endogenous HTT gene that recapitulate Huntington's Disease in humans. Furthermore, the cell lines have isogenic controls that share a similar genetic background. Differentiating cell lines committed to a neuronal fate and fully differentiated cell lines are also provided and they also display phenotypic abnormalities associated with the length of the polyQ repeat of the HTT gene. These cell lines are used as screening tools in drug discovery and development to identify substances that fully or partially revert these phenotype abnormalities.
Type:
Application
Filed:
February 24, 2017
Publication date:
June 27, 2019
Applicant:
The Rockefeller University
Inventors:
Ali BRIVANLOU, Albert RUZO, Alessia DEGLINCERTI, Tomomi HAREMAKI, Fred ETOC
Abstract: An optical system for the detection of skin disease, such as melanoma, acquires images of a lesion on a subject's skin at different wavelengths and utilizes a sweeping arm rotating about the lesion in a clock-like sweep to produce diagnostically relevant metrics and classifiers from the image data so as to enhance detection of the skin disease.